Hiroki Sugita

Hiroki Sugita is a partner in Orrick’s Tokyo Office and a member of the M&A and Private Equity Group. He works on a wide range of cross-border transactions including mergers and acquisitions, joint ventures, emerging companies and venture capital transactions, and private equity investment especially in Japan, the United States, Europe and Asia.

• Engagements

  Mergers and Acquisitions (Cross-border)

  • Representation of a Japanes biopharmaceutical company the JPY65 billion acquisition of Swiss pharmaceuticals business in Japan and APAC.
  • Representation of a Japanese cryptocurrency exchange company on its sale to a crypto derivative exchange company.
  • Representation of a Japanese chemical company in its acquisition of 45% stakes in a leading Japanese manufacturer of specialty chemicals, from a U.S.-based global technology and specialty material company.
  • Representation of a Japanese developer and manufacturer of medical devices in its 50% share acquisition of a regulatory, clinical and reimbursement consultancy in Japan.
  • Advised a Japanese chemical company in an agreement to acquire the plant health business from a global animal health company.
  • Representation of a Japanese chemical manufacturer in the acquisition of a German insulation systems manufacturer.
  • Representation of food products manufacturer in Japan in its agreement with a major producer and seller of chemical products, and a company that imports and sells infant formula, both from Asia to form a joint venture for producing and selling powdered infant formula in Asia.
  • Representation of a U.S. investment bank in its acquisition of a golf course redevelopment project in Japan.
  • Representation of a leading U.S. manufacturer of high-performance semiconductors in the acquisition of a high-performance filter business from Panasonic Corporation, through corporate separation.
  • Representation of a leading U.S. manufacturer and supplier of electronic components, in the acquisition of a Japanese electronic parts company.
  • Representation of a major Japanese trading firm, in the investment in an Indonesia-based high-speed network company.
  • Representation of a Japanese information and communication technology service provider and a Japanese trading firm, in their investment in an Indonesia-based data center company.
  • Representation of a leading hard drive manufacturer in its $4.8B acquisition of a Japanese hard disk drive manufacturer.
  • Representation of a Japan based online game company in its acquisition of various online game content companies.
  • Representation of a global food and beverage producer based in Japan in its acquisition of allergy-oriented, hypoallergenic nutritional supplement company through a public tender offer.
  • Representation of a Japan based electronic and electronics equipment manufacturer in its acquisition of a Japan subsidiary of a U.S. based electronic and electrical interconnect system supplier.

  Private Equity and Venture Capital (Cross-border)

  • Representation of a Japanese multinational automotive manufacturer on its US$400 million investment　into an autonomous vehicle technology company co-located in the United States and China.
  • Representation of a financial service company in their investment of a Massachusetts based company that developed small molecule drugs intended to activate progenitor cells within the body to restore and regenerate tissues.
  • Representation of a cryptocurrency exchange company, the second “unicorn” in Japan’s startup space, in their Series C funding.
  • Representation of major Japanese general trading company in the establishment of a corporate venture capital fund with a California-based venture capital firm.
  • Representation of a Japanese company targeting innovations in oncology, CNS and autoimmune disease, in their US$4.9 million Series A financing.
  • Representation of the largest Japan-based manufacturer of cranes in its LP investment in a US venture fund.
  • Representation of a startup developing AI learning in virtual space, in raising over JPY 2 billion from domestic and foreign investors.
  • Representation of a Tokyo based start-up on its pre-A round of US$3 million.
  • Assisted in the formation of a fund with a JPY 10 billion target to invest in unlisted venture companies in Japan and overseas, mainly in the bio-healthcare and numerous following investments, as part of the first project for the "Global alliance Promotion Scheme" advocated by the Ministry of Economy, Trade and Industry in Japan.
  • Representation of a venture capital fund in their investment in a Japanese pharmaceutical company for their Series A round.
  • Representation of a French venture company in their JPY 1.45 billion investment into a Japan-based pharmaceutical venture company.
  • Representation of a Japan-based travel agency in their strategic B investment in a Taiwanese online travel start up.
  • Representation of a venture company in its investment into the US$7.3 million Series A round for a Japanese developer of a cloud-based satellite-antenna sharing platform.
  • Representation of a Japanese trading firm in its strategic investment into a leading U.S. cross-device identity management technology startup.
  • Representation of a Japan and Silicon Valley based deep-learning fintech company in its sale of an image web service, and in its $1.7 million seed financing.
  • Representation of a Japanese trading firm in venture investment in a China-based drug research and development company.
  • Representation of a Japanese trading firm in investment in a China-based energy storage company.
  • Representation of a U.S.-based venture capital in its series B investment into a Japanese IoT company.
  • Representation of a Japanese trading firm in its investment in a Chinese fund.
  • Representation of Coller Capital in its investment in Pfizer Japan’s spin-off company through subscription of shares and warrants
  • Representation of foreign sovereign fund in its investment in a licensed securities company in Japan through convertible preferred stock subscription.